Nelfinavir, a new protease inhibitor: early clinical results.

  title={Nelfinavir, a new protease inhibitor: early clinical results.},
  author={William G. Powderly and Pablo Tebas},
  volume={13 Suppl 1},
Nelfinavir is a potent inhibitor of the HIV-1 protease, which shows good inhibitory activity against HIV-1 in vitro. Initial clinical trials have shown that it has excellent activity in vivo in HIV-infected patients. The combination of 750 mg nelfinavir three times daily with zidovudine and lamivudine has been shown to cause a median reduction in HIV plasma… CONTINUE READING